CASE REPORTS

Penile melanoma
Melanoma peniano
Luiz Felipe de Mello Pereira Leitão¹, Fernanda Monteiro Orellana¹, João Pedro Vaz de Souza Cabral Simões¹, Rute Facchini Lellis², Marcus Maia³, Roni de Carvalho Fernandes¹, Luis Gustavo Morato de Toledo¹

1.Irmandade Santa Casa de Misericórdia de São Paulo, Urology - Sao Paulo, - Brazil
2.Irmandade Santa Casa de Misericórdia de São Paulo, Pathology - Sao Paulo, Sao Paulo, Brazil
3.Irmandade Santa Casa de Misericórdia de São Paulo, Dermatology - Sao Paulo, Sao Paulo, Brazil

ABSTRACT
Penile melanoma is a rare event, responsible for less than 1.4% of penile cancers. In general, it is late diagnosed and the treatment is usually aggressive. The authors present a 66-year-old Caucasian man who had an ulcerated penile lesion for 1 year, diagnosed as melanoma after biopsy and treated as locally advanced disease with partial penectomy, identification of the sentinel lymph node and bilateral inguinal lymphadenectomy.

Keywords: Melanoma; Penis; Penile neoplasms; Surgical treatment; Penectomy; Sentinel lymph node.

RESUMO
O melanoma peniano é um evento raro, responsável por menos de 1,4% dos cânceres penianos. No geral, o diagnóstico é tardio e o tratamento costuma ser agressivo. Os autores apresentam um homem de 66 anos de idade, caucasiano, com lesão peniana ulcerada há 1 ano, diagnosticada como melanoma após biópsia e tratada como doença localmente avançada com penectomia parcial, identificação do linfonodo sentinel e linfadenectomia inguinal bilateral.

Descritores: Melanoma; Pênis; Neoplasias penianas; Tratamento cirúrgico; Penectomia; Linfonodo sentinel.

Financial support: none to declare.
Conflicts of interest: The authors declare no conflict of interest relevant to this manuscript.
Correspondence author: Luiz Felipe de Mello Pereira Leitão. E-mail: luizfleitao@yahoo.com.br / luizleitaosc@gmail.com

Received on: July 9, 2020 | Accepted on: October 28, 2020
DOI: https://doi.org/10.5935/2526-8732.20200040
INTRODUCTION

Primary penile melanoma is an aggressive and rare neoplasm (less than 1.4% of primary penile cancers) that affects patients in the sixth and seventh decade of life.\(^1,2\) The first case was described by Muchison, in 1859.\(^3\) Histologically, it is classified as cutaneous or mucous (most frequent). The cutaneous melanoma compromises 9% of the cases and it is located on the penile shaft. The mucous melanoma is located mainly in the glans (55%), foreskin (28%), and urethral meatus (8%).\(^4\) The curative treatment is related to the excision of the tumor in its initial growth phase, so the requirement for an early diagnosis of these lesions is well established.

CASE REPORT

A 66-year-old Caucasian, male, non-smoker, from the city of São Paulo, attended the urology department due to an injury to the penile glans of insidious growth for 1 year. There were no other associated symptoms. On physical examination, he had a 1cm, ulcerated, painless, hyperpigmented penile lesion surrounded by satellite lesions. There were no palpable perilesional lymph nodes or inguinal region (Figure 1).

The patient underwent dermoscopy, a method for visualizing the structures located below the stratum corneum, being characterized as a hyperpigmented melanocytic lesion (Figure 2).

The anatomopathological showed a 7mm thick Clark IV nodular melanoma, with ulceration, without angiolymphatic and perineural invasion. Clinical staging of the disease was performed with chest X-ray, abdominal and pelvis tomography (CT) and cranial magnetic resonance imaging (MRI), with no evidence of regional lymph node enlargement or systemic metastases. Due to the locally advanced clinical stage (T4bN0M0 – ulcerated lesion above 4mm), PET/CT was performed, whose uptake also did not show lymph node or systemic disease. The authors performed partial penectomy and investigation of sentinel lymph node with local technetium injection 12 hours before the procedure (Figure 3), in addition to bilateral inguinal lymphadenectomy at the same surgical time, due to the absence of clinical evidence in the literature that proves the total effectiveness of the sentinel lymph node in the identification of lymph node micrometastasis of penile melanoma, since the lymphatic drainage of the penis is crossed, as it is a midline organ. The margin was subsequently enlarged by 2cm due to impairment (Figure 4).

There are microscopic satellite lesions that represent non-nodal regional tumor spread - pT3b pN1c pM0. The sentinel lymph node and the lymphadenectomy products showed reactive lymphoid hyperplasia,
Primary penile melanoma (MPP) is a rare neoplasm that affects less than 1.4% of primary penile carcinomas and affects mainly patients in the sixth and seventh decade of life. According to the histological origin of the tumor, penile melanomas can be divided into cutaneous and mucous. The cutaneous subtype is located on the penile shaft and corresponds to 9% of the locations. The mucous subtype is located in the glans (55%), foreskin (28%) and urethral meatus (8%). One of the greatest challenges of MPP is its early diagnosis, since its initial presentation may be indistinguishable from benign injury. MPP can present as a black, brown, bluish, reddish or even amelanotic pigmented lesion. Therefore, any suspicious lesion should be biopsied early.

Several case reports describe the poor prognosis of primary penis melanoma, with 50% of patients already having some type of metastasis at the time of diagnosis. The main factors of poor prognosis are: presence of ulceration, lymph node involvement, presence of microsatellite invasion, thickness greater than 3.5mm and diameter greater than 15mm. The overall survival rate at 2 and 5 years is described at 63% and 31%, respectively. The most accepted classification for melanoma follows the protocol established by the American Joint Committee on Cancer. Depth and the presence of ulceration are the most relevant factors in the TNM classification. Between the 1970s and 1980s, treatment involved radical surgery (total penectomy, perineal urethrostomy and inguinal, iliac and bilateral obturator lymphadenectomy). More recently, organ-sparing surgeries have become an option for individualizing treatment and consist of local excision, glandectomy, partial or total penectomy. Treatment may involve the investigation of sentinel lymph node, a technique that detects the first lymph node chain affected by possible metastasis and is an important in the prognosis of the disease, and that must be performed whenever there is a risk of hidden metastases.

Other alternatives to melanomas that cannot be surgically excised include cryotherapy, radiotherapy and topical treatments such as interferons, azelaic acid, and fluorouracil, but evolve with a higher rate of recurrence. Imiquimod is an immunomodulator for the production of cytokines induced by the Toll-like receptor 7, used to treat actinic keratoses and basal cell carcinoma. Topical off-label use of imiquimod is reported in cases of melanoma in situ and metastasis of cutaneous melanoma, with an acceptable success rate.

The prognosis for advanced disease is poor due to the low effectiveness of systemic chemotherapy. Chemotherapy cycles are described with dacarbazine, carmustine, cisplatin and tamoxifen with an overall response rate of 45%. The use of interferon reduces recurrence and increase the overall survival rate in advanced disease. More recently, tyrosine kinase inhibitors and immunotherapy with checkpoint inhibitors (anti-CTLA4, anti-PD-1 and anti-PDL-1) have been used as adjuvant therapy after surgical resection to increase overall survival but due to the rarity of primary penis melanoma, there is no confirmation of safety and efficacy in this scenario.

BRAF, a cytosolic protein kinase, whose activation leads to cell proliferation, was detected in melanomas outside the penis, enabling targeted therapy with some success. In a recent review, 12 patients with penile melanomas underwent DNA analysis, but none of these samples showed mutations in BRAF or activation mutations in exons 11, 13, 17 or 18 of the KIT. Reviewing the literature, we did not find evidence of BRAF mutation in a series of penile melanomas. Primary radiotherapy (RT) can be considered in cases where resection is not possible, although most studies of RT involved few cases, short segment time and different doses of RT.

CONCLUSION
Malignant melanoma of the penis is a rare disease whose incidence of metastasis is high due to the delay in diagnosis, and as a result, has low overall survival rates, even when it is treated. The gold standard treatment is resection of the lesion with organ-sparing surgery when possible. The investigation of sentinel lymph node and inguinal lymphadenectomy may be necessary depending on the stage of the lesion. The reported case shows a locally advanced penis melanoma whose treatment was partial penectomy, lymphadenectomy and margin enlargement, in an oncological follow up.

ACKNOWLEDGMENTS
To the entire urology team at Santa Casa de São Paulo.

REFERENCES
1. Baraziol R, Schiavon M, Fracalanza E, De Giorgi G. Melanoma in situ of penis. Medicine. 2017 Sep;96(36):e7652.
2. Oldbring J, Mikulowski P. Malignant melanoma of the penis and male urethra: report of nine cases and review of the literature. Cancer. 1987 Feb;59(3):581-7.
3. Bechara GR, Schwindt ABS, Ornellas AA, Silva DEA, Lott FM, Campos FS. Penile primary melanoma: analysis of 6 patients treated at Brazilian national cancer institute in the last eight years. Int Braz J Urol. 2013 Dec;39(6):823-31.

4. Li Y, Yuan H, Wang A, Zhang Z, Wu J, Wei Q. Malignant melanoma of the penis and urethra: one case report. World J Surg Oncol. 2014;12(1):340.

5. Van Geel AN, den Bakker MA, Kirkels W, Horenblas S, Kroon BBR, Wilt JHW, et al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature Urol. 2007 Jul;70(1):143-7.

6. Jabiles AG, Del Mar EY, Perez GAD, Vera FV, Montoya LM, Deza CMM. Penile melanoma: a 20-year analysis of six patients at the National Cancer Institute of Peru, Lima. Ecancer. 2017;11:731.

7. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec;27(36):6199-206.

8. Miller E, Barnea Y, Karin E, Leshem D, Weiss J, Leider-Trejo L, Schneebaum S. Sentinel lymph node biopsy in the diagnosis and treatment of multicentric malignant melanoma of the penis. Isr Med Assoc J. 2009 Apr;8(4):292-3.

9. Napolitano M, Annessi G, Didona D, Didona B. Multifocal melanoma in situ of the penis treated with topical Imiquimod. J Eur Acad Dermatol Venereol. 2016 Mar;30(3):458-60.

10. Yang A, Klapman M, Cassarino DS. Spontaneously regressing primary nodular melanoma of the glans penis. Cutis. 2014 Oct;94(4):E9-E11.

11. Napolitano M, Annessi G, Didona D, Didona B. Multifocal melanoma in situ of the penis treated with topical Imiquimod. J Eur Acad Dermatol Venereol. 2016 Mar;30(3):458-60. DOI: https://doi.org/10.1111/jdv.12835

12. Oxley JD, Corbishley C, Down L, Watkin N, Dickerson D, Wong NACS. Clinicopathological and molecular study of penile melanoma. J Clin Pathol. 2012 Mar;65(3):228-31. DOI: https://doi.org/10.1136/jclinpath-2011-200344